Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Of the total of 1795 subjects randomized in Clarity AD, 294 subjects were in the Asian region (Japan:152; Korea:129; Singapore:13). The efficacy of lecanemab was consistent with the overall population. For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region (adjusted mean difference: -0.349; 95 % confidence intervals: -0.773, 0.076; 24 % slowing of decline). Results for the secondary efficacy endpoints also favored lecanemab versus placebo in Asians. Lecanemab was well tolerated in Asian subjects, with a safety profile in Asian subjects similar to the overall Clarity AD population. The most common adverse events of special interest were ARIA-H (lecanemab:14.4 %; placebo:16.2 %), ARIA-E (lecanemab:6.2 %; placebo:1.4 %), and infusion-related reactions (lecanemab:12.3 %; placebo:1.4 %). Incidence of adverse events leading to study drug dose interruption or withdrawal, infusion-related reactions, ARIA-E and ARIA-H was lower for the lecanemab treated group in the Asian region relative to the overall Clarity AD population. Results from quality of life and biomarker assessments in the Asia region were also generally similar to the overall Clarity AD population. In the Clarity AD Asian region cohort, the overall efficacy, biomarker changes and safety profile of lecanemab were consistent with the overall population, with a favorable risk-benefit profile and manageable risks. ARIA events and infusion-related reactions occurred less commonly with lecanemab in the Asian region subgroup than the overall population.

What this study adds

Evidence grade: High

This is a trial of 294 participants. In the Asian region portion of the phase III Clarity AD trial (294 of 1795 participants), lecanemab slowed decline on the CDR-SB at 18 months compared with placebo, with a safety profile similar to the overall trial population. This supports lecanemab's use in early Alzheimer's disease but does not show it cures or prevents the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chen, C., Katayama, S., Lee, J. H., Lee, J.-Y., Nakagawa, M., Torii, K., et al. (2025). Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100160

Vancouver

Chen C, Katayama S, Lee JH, Lee J.-Y, Nakagawa M, Torii K, et al. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100160. PMID: 40189473.

BibTeX

@article{chen2025-40189473,
  author  = {Chen, Christopher and Katayama, Sadao and Lee, Jae Hong and Lee, Jun-Young and Nakagawa, Masaki and Torii, Kentaro and Ogawa, Tomoo and Dash, Amitabh and others},
  title   = {{Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100160},
  pmid    = {40189473},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100160}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In the Asian region portion of the phase III Clarity AD trial (294 of 1795 participants), lecanemab slowed decline on the CDR-SB at 18 months compared with placebo, with a safety profile similar to the overall trial population. This supports lecanemab's use in early Alzheimer's disease but does not show it cures or prevents the disease.

Study details

How this study scored 58/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 58 of 100.58 of 100 points earned42 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 294 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 45 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 15.0 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 24.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 2 / 4 Cited 45 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Takeshi Iwatsubo: h-index 115 (OpenAlex, whole career)
Institution's track record 1 / 3 The University of Tokyo: institution h-index 1,463 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40189473)
Free to read 2 / 2 Free to read
Total 58 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →